

Date: 24/12/2015

FREEDOM OF INFORMATION REQUEST FOI/012556 - Biologics and biosimilars

I have a Freedom of Information request regarding biologics and biosimilar prescribing.

1. Does your trust run a dedicated Gastroenterology infusion clinic for the treatment of patients with Infliximab [or Vedolizumab] If Yes, how frequently are they run ?

No dedicated gastroenterology infusion clinics. Each patient is assessed and we organise a date and time that suits the patient during a working week. Our medical day case ward is open from 08.30 to 20.00 5 days a week. We can normally arrange infusions within 5-7 days of approval for the drug.

2. Could you please provide me with the following numbers of patients treated in the last six months with the following drugs for the conditions listed below.

	Rheumatology [Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis]	Dermatology [Psoriasis]	Hidradeniti s suppurativa (sometimes known as acne inversa) L73.2	Gastroenterolog y  [Crohns / Ulcerative Colitis]
Abatacept (Orencia)	21	0	0	0
Adalimumab (Humira)	148	n/a	0	79
Apremilast (Otezla)	n/a	0	0	0
Certolizumab Pegol (Cimzia)	14	0	0	0
Etanercept (Enbrel)	197	n/a	0	0
Golimumab (Simponi)	32	0	0	6
Infliximab (Remicade)	15		0	28
Infliximab biosimilar (Inflectra)	0	0	0	0
Infliximab biosimilar (Remsima)	0	0	0	0

Rituximab (MabThera)	51	0	0	0
Secukinumab (Cosentyx)	0	n/a	0	0
Tocilizumab (RoActemra)	28	0	0	0
Tofacitinib [Xeljanz]	0	0	0	0
Ustekinumab (Stelara)	1	n/a	0	0
Vedolizumab (Entyvio)	n/a	0	0	9